Guggenheim Capital’s Alimera Sciences ALIM Stock Holding History

Guggenheim Capital’s Portfolio ALIM Stock Details ALIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,133	Closed	-$17K	–	2648
2018 Q1	$17K	Buy	1,133 +7	+0.6%	+$124	﹤0.01%	2753
2017 Q4	$22K	Sell	1,126 -140	-11%	-$2.73K	﹤0.01%	2668
2017 Q3	$26K	Buy	1,266 +2	+0.2%	+$43	﹤0.01%	2731
2017 Q2	$26K	Hold	1,264	–	–	﹤0.01%	2770
2017 Q1	$27K	Buy	1,264 +27	+2%	+$520	﹤0.01%	2762
2016 Q4	$20K	Hold	1,237	–	–	﹤0.01%	2849
2016 Q3	$28K	Buy	+1,237	New	+$28.5K	﹤0.01%	2796
2016 Q1	–	Sell	-2,006	Closed	-$74K	–	3007
2015 Q4	$74K	Buy	2,006 +1,194	+147%	+$51.8K	﹤0.01%	2865
2015 Q3	$27K	Buy	+812	New	+$45.7K	﹤0.01%	2882
2014 Q2	–	Sell	-747	Closed	-$88K	–	3317
2014 Q1	$88K	Buy	+747	New	+$72.6K	﹤0.01%	3048

Other funds holding ALIM

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Guggenheim Capital's ALIM Position: Q2 2018 in Review

Guggenheim Capital sold out of Alimera Sciences (ALIM) in Q2 2018, closing a stake of 1,133 shares — an estimated $17K sold.

Guggenheim Capital first reported a position in ALIM in Q1 2014 and held it in 10 quarters. The position peaked at $88K in Q1 2014. 37 funds tracked by Wall St. Rank hold ALIM as of Q2 2018.

Guggenheim Capital reported no remaining Alimera Sciences position as of Q2 2018 after selling out during the quarter.
Guggenheim Capital sold 1,133 Alimera Sciences shares in Q2 2018, an estimated $17K.
Guggenheim Capital first reported a position in Alimera Sciences in Q1 2014 and held it in 10 quarters.
Guggenheim Capital's Alimera Sciences position peaked at $88K in Q1 2014.
37 funds tracked by Wall St. Rank held Alimera Sciences as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.